DeepaJeyakumarMD

Oncology • Orange, CA

Hematologic Oncology

Associate Clinical Professor

Join to view full profile

Dr. Jeyakumar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Jeyakumar's full profile

Already have an account?

Office
101 The City Dr S
Bldg 23
Orange, CA 92868
Phone+1 714-456-5153

Education & Training

Stanford Health CareFellowship, Blood & Bone Marrow Transplant, 2012 - 2013
Tufts Medical CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
University of Illinois College of Medicine at ChicagoResidency, Internal Medicine, 2005 - 2008
Lewis Katz School of Medicine at Temple UniversityClass of 2005

Certifications & Licensure

CA State Medical License 2012 - 2025
MA State Medical License 2009 - 2013
IL State Medical License 2005 - 2011
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
Completed
Phase 3
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma Start of enrollment: 2013 Aug 27
Active, not recruiting
Phase 2
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia Start of enrollment: 2014 May 19
Active, not recruiting
Phase 3
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2014 Feb 20
Active, not recruiting
Phase 3
Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome Start of enrollment: 2016 May 17
Completed
Phase 1
CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia Start of enrollment: 2020 Feb 19
Recruiting
Phase 2
CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia Start of enrollment: 2019 Jul 18
Terminated
Phase 1
Roles: Contact, Principal Investigator
Use of Levocarnitine to Reduce Asparaginase Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia Start of enrollment: 2023 Mar 03
Recruiting
Early Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial.
Caspian Oliai, Sunmin Park, Lloyd E Damon, Brian A Jonas, Deepa Jeyakumar
Leukemia & Lymphoma. 2024-12-17
Extending duration of letermovir prophylaxis in haploidentical stem cell transplantation.
Pongthep Vittayawacharin, Benjamin J Lee, Shawn Griffin, Jean Doh, Julie Smith
Haematologica. 2024-11-01
Intensification of upfront chemotherapy for patients with myeloid blast phase CML: a single center experience.
Benjamin J Lee, Shawn P Griffin, Jean Doh, Stefan O Ciurea, Deepa Jeyakumar
Annals of Hematology. 2024-10-23

Journal Articles

Prolymphocytic Transformation of Lymphoplasmacytic Lymphoma; An Extremely Unusual Event
Kuixing Zhang, Daniel Farrell, Deepa Jeyakumar, Sherif A Rezk, ScienceDirect

Abstracts/Posters

Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California Hematolo...
Deepa Jeyakumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019